# Capmatinib & tepotinib

Source: https://onco.cc/drugs/capmatinib-tepotinib/  
OnCo record `capmatinib-tepotinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Capmatinib and tepotinib are two pills for the roughly 3% of lung cancers with a MET exon 14 skipping mutation.

## Summary

Capmatinib and tepotinib are type Ib MET inhibitors that bind only the active conformation of the MET kinase, sparing other kinases. They treat the roughly 3% of non-small-cell lung cancers driven by a MET exon 14 skipping mutation, in both untreated and previously treated patients. Capmatinib (GEOMETRY mono-1: ORR 68% treatment-naive) was approved in 2020 with full approval in 2022; tepotinib (VISION: ORR ~57%) was approved in 2021 with full approval in 2024. Peripheral oedema is the class toxicity and often needs dose adjustment. MET amplification as an EGFR-TKI escape route is a different problem and is instead addressed by amivantamab and MET ADCs. The simple version: test lung adenocarcinomas for MET exon 14 skipping, because two pills work well when it is present.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-06
- Brand: Tabrecta / Tepmetko
- Modality: Small-molecule kinase inhibitors (MET)
- Mechanism: Highly selective type Ib MET inhibitors.
- Approvals: US 2020: MET exon 14 skipping NSCLC (capmatinib; tepotinib 2021); EU 2022: Tepmetko 2022; Tabrecta 2022

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Capmatinib
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Capmatinib%20%26%20tepotinib

## Connected records

- cancers: [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [MET](https://onco.cc/targets/met/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/), [Novartis](https://onco.cc/companies/novartis/)
- trials: [GEOMETRY mono-1](https://onco.cc/trials/geometry-mono-1/), [VISION (tepotinib)](https://onco.cc/trials/nct02864992/)
- people: [Jürgen Wolf](https://onco.cc/people/juergen-wolf/)
- pathways: [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/)
- biomarkers: [MET exon 14 skipping mutation](https://onco.cc/biomarkers/met-ex14/)

---
JSON: https://onco.cc/api/v1/entities/capmatinib-tepotinib.json